drugset / Trial / NCT07143604

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

NCT07143604

Phase 2 Active not recruiting 33 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Timeline

Start
2025-08-29
Primary completion
2026-09-28
Completion
2027-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Sonesitatug Vedotin Other / unclassified Intravenous